Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Albertsons Companies Inc (ACI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Albertsons Companies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Albertsons Companies Inc trades at $12.35 (market cap $5.89B). The key difference: Albertsons Companies Inc is the larger of the two by market cap, and Albertsons Companies Inc pays a 5.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ACI | |
|---|---|---|
Market Cap | $5.06B | $5.89B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $19.74 |
52-Week Low | $20.06 | $11.03 |
Enterprise Value | $4.18B | $21.29B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Albertsons (ACI) trades at $12.01, down 0.58% with bearish technical signals despite recent insider buying by the CEO and CFO. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains strong revenue growth trends. Valuation metrics show a high P/E ratio of 75.06 but attractive P/S of 0.08, while profitability remains challenged with net margins at just 0.08%.
The outlook remains cautious with analyst consensus at Buy (35%) but significant legal investigations and margin pressure creating headwinds. The $13.20 price target offers 10% upside potential, though execution risks and competitive grocery market dynamics require careful monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →
